Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics


Genetron Holdings Ltd. ADR (GTH): $20.64

0.76 (+3.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GTH POWR Grades


  • Sentiment is the dimension where GTH ranks best; there it ranks ahead of 90.51% of US stocks.
  • The strongest trend for GTH is in Stability, which has been heading down over the past 31 weeks.
  • GTH's current lowest rank is in the Quality metric (where it is better than 4.73% of US stocks).

GTH Stock Summary

  • Genetron Holdings Ltd's stock had its IPO on June 19, 2020, making it an older stock than only 0.58% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -29.65 for Genetron Holdings Ltd; that's greater than it is for only 0.81% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GTH comes in at -95.98% -- higher than that of just 2.32% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Genetron Holdings Ltd are SESN, VVV, LEE, HZN, and FLXN.
  • To dig deeper into the stock's financial statements, go to GTH's page on browse-edgar?action=getcompany&CIK=0001782594.

GTH Stock Price Chart Interactive Chart >

Price chart for GTH

GTH Price/Volume Stats

Current price $20.64 52-week high $31.54
Prev. close $19.88 52-week low $9.03
Day low $19.71 Volume 153,569
Day high $20.80 Avg. volume 364,960
50-day MA $20.26 Dividend yield N/A
200-day MA $17.58 Market Cap 1.83B

Genetron Holdings Ltd. ADR (GTH) Company Bio


Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.


GTH Latest News Stream


Event/Time News Detail
Loading, please wait...

GTH Latest Social Stream


Loading social stream, please wait...

View Full GTH Social Stream

Latest GTH News From Around the Web

Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.

Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were from studies that Genetron Health conducted in partnershi

Yahoo | June 4, 2021

Genetron Holdings Limited 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Genetron Holdings Limited in conjunction with their 2021 Q1 earnings call....

SA Transcripts on Seeking Alpha | May 24, 2021

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair.

Yahoo | May 13, 2021

Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021

Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 22 research results at the American Association for Cancer Research Annual Meeting 2021 (AACR 2021).

Yahoo | April 13, 2021

Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologi...

Yahoo | April 1, 2021

Read More 'GTH' Stories Here

GTH Price Returns

1-mo 6.34%
3-mo -10.34%
6-mo 54.49%
1-year N/A
3-year N/A
5-year N/A
YTD 47.43%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8107 seconds.